Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

GSK buys rights to Tolerx's diabetes antibody otelixizumab

Executive Summary

GlaxoSmithKline has gotten exclusive worldwide rights to immunology company Tolerx's lead monoclonal antibody otelixizumab (TRX4), which is in Phase II for Type I diabetes and in Phase I for psoriasis.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Co-Promotion

Related Companies

UsernamePublicRestriction

Register